Pancreatic Cancer Research

ResearcherYokohama City UniversityActive in the last 2 years

Naoto Yamamoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0613-5451; OpenAlex author ID A5022033467. Sources: OpenAlex.

Their work

Papers
30 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
57
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: 4 papers · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 4 papers · 2021: none · 2022: 1 paper · 2023: 3 papers · 2024: 7 papers · 2025: 4 papers

Papers 30

  1. Optimal treatment strategy for patients with pancreatic cancer having positive peritoneal cytology: A nationwide multicenter retrospective cohort study supervi… Co-author DOI 10.1002/jhbp.12074↗
  2. Peritoneum carcinomatosis as a favourable prognostic factor for treatment with nanoliposomal irinotecan and fluorouracil plus leucovorin in advanced pancreatic… Co-author DOI 10.1177/17588359251351540↗
  3. Overexpression of Nuclear Factor of Activated T-cells (NFAT) Transcription Factors Drives Chemoresistance and Poor Outcomes in Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18186-9↗
  4. Significance of Preoperative Chemotherapy and Chemoradiotherapy in Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer. Co-author DOI 10.21873/anticanres.17804↗
  5. Clinical usefulness of C-reactive protein-albumin-lymphocyte (CALLY) index as a prognostic biomarker in patients undergoing surgical resection of pancreatic ca… Co-author DOI 10.1007/s00423-024-03512-8↗
  6. Evaluation of pancreatic cancer specimens for comprehensive genomic profiling. Co-author DOI 10.1111/pin.13416↗
  7. A multi-institutional randomized phase III study comparing minimally invasive distal pancreatectomy versus open distal pancreatectomy for pancreatic cancer; Ja… Co-author DOI 10.1186/s12885-024-11957-9↗
  8. Prognostic nutritional index is an independent risk factor for continuing S-1 adjuvant chemotherapy in patients with pancreatic cancer who received neoadjuvant… Co-author DOI 10.1186/s12885-024-13244-z↗
  9. Clinical Impact of Preoperative Neutrophil-to-Lymphocyte Ratio in Surgical Patients With Pancreatic Cancer. Co-author DOI 10.21873/anticanres.16805↗
  10. Clinical Impact of Preoperative Prognostic Nutritional Index in Surgical Patients With Pancreatic Cancer Treated With Perioperative Adjuvant Chemotherapy. Co-author DOI 10.21873/anticanres.16970↗
  11. Loss of Skeletal Muscle Mass During Neoadjuvant Chemotherapy for Pancreatic Cancer Is Related to the Continuation of S-1 Adjuvant Chemotherapy After Pancreatec… Co-author DOI 10.21873/anticanres.17286↗
  12. Risk factors for early recurrence in patients with pancreatic ductal adenocarcinoma who underwent curative resection. Co-author DOI 10.1186/s12957-023-03141-3↗
  13. Carbon Ion Radiotherapy Versus Perioperative Adjuvant Chemotherapy and Curative Surgery for Resectable Pancreatic Cancer. Co-author DOI 10.21873/anticanres.16222↗
  14. Incidence and Risk of Venous Thromboembolism in Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy. Co-author DOI 10.21873/anticanres.16327↗
  15. Postoperative acute pancreatitis after pancreatic resection in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00423-022-02481-0↗
  16. Novel targets identified by integrated cancer-stromal interactome analysis of pancreatic adenocarcinoma. Co-author DOI 10.1016/j.canlet.2019.10.031↗
  17. Clinical Implication of Pre-operative C-reactive Protein-Albumin Ratio as a Prognostic Factor of Patients With Pancreatic Ductal Adenocarcinoma: A Single-insti… First author DOI 10.21873/invivo.11780↗
  18. The Impact of Intraoperative Blood Loss on the Survival of Patients With Stage II/III Pancreatic Cancer. Co-author DOI 10.21873/invivo.11931↗
  19. The age-adjusted Charlson comorbidity index is an independent prognostic factor in pancreatic cancer patients who receive curative resection followed by adjuva… First author DOI 10.4103/jcrt.jcrt_440_18↗
  20. The impact of SPARC expression on the survival of pancreatic ductal adenocarcinoma patients after curative resection. Co-author DOI 10.7150/jca.28660↗
  21. The Lymph Node Ratio Is an Independent Prognostic Factor in Pancreatic Cancer Patients Who Receive Curative Resection Followed by Adjuvant Chemotherapy. First author DOI 10.21873/anticanres.12801↗
  22. Clinical implications of dihydropyrimidine dehydrogenase expression in patients with pancreatic cancer who undergo curative resection with S-1 adjuvant chemoth… Co-author DOI 10.3892/ol.2017.6295↗
  23. [Safety and Feasibility of Pancreatic Surgery for Pancreatic Cancer in Elderly Patients]. Co-author PMID 28133043↗
  24. Safety and feasibility of S-1 adjuvant chemotherapy for pancreatic cancer in elderly patients. Co-author DOI 10.1007/s00280-015-2736-5↗
  25. Impact of postoperative complications on survival and recurrence in pancreatic cancer. Co-author PMID 25862906↗
  26. Clinical implication of peritoneal cytology in the pancreatic cancer patients who underwent curative resection followed by adjuvant gemcitabine or S-1 chemothe… Co-author PMID 25911897↗
  27. [The Safety and Feasibility of Conversion Surgery for Initially Unresectable Pancreatic Cancer]. Co-author PMID 26805070↗
  28. Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancer. Co-author DOI 10.1007/s00280-014-2601-y↗
  29. The clinical significance of SWI/SNF complex in pancreatic cancer. Co-author DOI 10.3892/ijo.2012.1723↗
  30. Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adju… Co-author DOI 10.1245/s10434-011-2054-z↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Makoto Ueno · 22 shared papers, 2014–2025 · strength 3.01
  2. Masaaki Murakawa · 24 shared papers, 2014–2025 · strength 2.90
  3. Soichiro Morinaga · 26 shared papers, 2012–2025 · strength 2.84
  4. Shinnosuke Kawahara · 10 shared papers, 2022–2025 · strength 1.71
  5. Satoshi Kobayashi · 13 shared papers, 2014–2025 · strength 1.57
  6. Yuto Kamioka · 9 shared papers, 2020–2025 · strength 1.45
  7. Toru Aoyama · 15 shared papers, 2014–2025 · strength 1.28
  8. Mariko Kamiya · 9 shared papers, 2018–2025 · strength 1.26
  9. Takashi Oshima · 10 shared papers, 2015–2024 · strength 0.96
  10. Hiroshi Tamagawa · 10 shared papers, 2012–2024 · strength 0.95
  11. Manabu Morimoto · 12 shared papers, 2014–2023 · strength 0.90
  12. Toru Aoyama · 4 shared papers, 2023–2024 · strength 0.69
  13. Yohei Miyagi · 7 shared papers, 2012–2025 · strength 0.69
  14. Yukihiko Hiroshima · 3 shared papers, 2020–2025 · strength 0.49
  15. Kota Washimi · 2 shared papers, 2024–2025 · strength 0.39
  16. Masakatsu Numata · 5 shared papers, 2013–2020 · strength 0.37
  17. Hiroshi Kurahara · 2 shared papers, 2024–2025 · strength 0.34
  18. Etsuro Hatano · 2 shared papers, 2024–2025 · strength 0.34
  19. Michiaki Unno · 2 shared papers, 2024–2025 · strength 0.34
  20. Robert M. Hoffman · 2 shared papers, 2020–2025 · strength 0.29
  21. Itaru Endo · 2 shared papers, 2020–2025 · strength 0.28
  22. Yuichiro Tozuka · 1 shared paper, 2025 · strength 0.22
  23. Junji Furuse · 1 shared paper, 2025 · strength 0.22
  24. Shun Tezuka · 1 shared paper, 2025 · strength 0.22
  25. Shin Maeda · 1 shared paper, 2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.